Beverly Hills Private Wealth LLC Sells 563 Shares of Sanofi $SNY

Beverly Hills Private Wealth LLC cut its position in shares of Sanofi (NASDAQ:SNY) by 3.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,460 shares of the company’s stock after selling 563 shares during the quarter. Beverly Hills Private Wealth LLC’s holdings in Sanofi were worth $795,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Ameritas Advisory Services LLC bought a new position in shares of Sanofi during the 2nd quarter valued at about $28,000. Accent Capital Management LLC bought a new position in shares of Sanofi during the 1st quarter valued at about $29,000. Eastern Bank increased its position in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after purchasing an additional 300 shares during the last quarter. Banque Transatlantique SA bought a new position in shares of Sanofi during the 1st quarter valued at about $33,000. Finally, Golden State Wealth Management LLC increased its position in shares of Sanofi by 619.3% during the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after purchasing an additional 545 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

Sanofi Price Performance

SNY opened at $49.73 on Tuesday. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. The stock’s 50 day simple moving average is $48.54 and its 200 day simple moving average is $49.55. The firm has a market cap of $122.11 billion, a price-to-earnings ratio of 11.95, a PEG ratio of 1.23 and a beta of 0.51.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion during the quarter, compared to analysts’ expectations of $9.91 billion. During the same quarter last year, the business posted $1.73 EPS. The company’s quarterly revenue was down 7.0% compared to the same quarter last year. As a group, analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SNY. Barclays reiterated an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, October 8th. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Finally, Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $62.67.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.